Company
LON:OPTI
OptiBiotix Health Plc is a life sciences company operating in one of the most progressive areas of biotechnological research. Developing and commercialising technologies that modulate the human microbiome – the collective genome of the microbes in the body – the company identifies and develops prebiotic formulations and compounds for use in food ingredients and supplements that can impact on human physiology and metabolism, deriving potential health benefits.
574 stories · page 3 of 29
OptiBiotix Health PLC (LON:OPTI) has developed technologies that modulate the human microbiome – the collective genome of the microbes in the body. It has done so by creating microbial strains, compounds and formulations for use in food ing
Genuine Health Inc will develop a product that it will submit for sign-off from Health Canada for cardiovascular and other claims
The licensing deal with weight management firm OptiPharm is bearing fruit, with the company launching meal replacement shakes and bars that contain OptiBiotix's OptiBiome technology
Aneta Zlotkowska will join the AIM-listed life sciences business at the beginning of 2021 and one of her primary objectives will be to attain a British Retail Consortium certification for OptiBiotix
OptiBiotix said the agreement was another example of the “increasing number of pharmaceutical companies commercialising CholBiome products into the high value GP, hospital and pharmacy markets”
The company's partner, Seed Health, has been given the regulatory green light to begin trials on a treatment that incorporates Lactobacillus Plantarum LPLDL
A glance at some of the day's highlights from the Proactive Investors newswire
The deal has been signed with United Italian Trading Corporation, a Singaporean pharmaceutical and medical device distribution firm
The update was provided alongside the company's interim results, which revealed its health products are gaining significant commercial traction
Optibiotix said the signing of the agreement with HiLife is subject to the placing of a trial order and a six month period after which both parties will discuss the terms of the agreement to explore online exclusivity for the USA
Ayalla Marketing, the company’s new partner, will distribute the cholesterol-reducing probiotic, LPLDL, as an ingredient and as four finished products
The new partner, whose identity is being kept confidential to protect its launch plans, has been granted an exclusive worldwide licence
Next-generation probiotic products are becoming aligned to an emerging concept of live drug biotherapeutic products, according to the company
The terms of the exclusive licence agreement originally granted OptiPharm exclusive use of the OptiBiome trademark in Australia, parts of Asia, New Zealand, Middle East, Gulf States and North America
Maxum Foods already has access to OptiBiotix’s SlimBiome and the OptiBiome products under an earlier manufacturing, supply and profit-sharing agreement
Agropur already has the rights to weight management range SlimBiome in the US, Canada and Mexico
OptiBiotix is expecting all of its divisions to break into the black this year
The number of territories covered by the agreement has been extended, as has the number of products
The company is a specialist in the human microbiome, the ecosystem of bacteria that resides in the gut and on the skin
WellBiome will now be added to the list of products distributed by CTC
